Dyslipidemia clinical trials

Explore recruiting dyslipidemia clinical trials.

Recruiting dyslipidemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Dyslipidemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction

Sweden

Therapeutic use (Phase IV) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with Mixed Dyslipidemia

Sweden, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Latvia, Italy, Estonia, Czechia, Finland, Netherlands +16 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk (MEDICI Study)

Spain, Poland, Netherlands, Italy, Slovakia, Czechia +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia

Poland, Hungary, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Dyslipidemia trials by city

Dyslipidemia in Toronto Dyslipidemia in Vancouver Dyslipidemia in Montreal Dyslipidemia in Calgary Dyslipidemia in Edmonton Dyslipidemia in Ottawa Dyslipidemia in Winnipeg Dyslipidemia in Quebec City Dyslipidemia in Hamilton Dyslipidemia in Kitchener Dyslipidemia in London Dyslipidemia in Halifax Dyslipidemia in New York Dyslipidemia in Los Angeles Dyslipidemia in Chicago Dyslipidemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease